NKTR News & Events

Investor sentiment is being seared by images of burning cargo ships blazing across the major media outlets last night and headlines out this afternoon that Iranian boats are placing mines to threaten commercial ships in a bid to choke off a major shipping route in the Strait of Hormuz and inflict economic damage on the West.  Equity markets finished the day near the lows with broad-based losses as Industrials and Consumer Cyclical sectors were hit especially hard.  Energy remains bid thanks to Crude Oil having ripped higher for the second consecutive day to trade above $96, while the Vix  has jumped north of the 27-handle.   Meanwhile, Treasuries are not attracting a flight to safety bid.  The yield on the 10-year Note is now near 4.3% - up almost 30 basis points from the Friday just before missiles were fired on Tehran - as implications of inflationary pressures stoked by higher oil prices muddy the outlook for renewed easing by the FOMC.In the opening hour of the evening session, the mood is less panicked for the time being as S&P 500 and Nasdaq 100 futures hold steady, up about 0.2%.  Precious metals are trading lower for the second consecutive day, tracking the strengthening inverse correlation with US Dollar as the greenback rallied once again.Among key afterhours earnings, Adobeinvestors were not enthused by the company's better than expected Q1 results, and the news of its CEO leaving after 18 years on the job compounded pressure on stock that has already been impacted by the AI-threat panic in the software space.  Shares are down over 7% and tested the downside of $250 level - the lowest since late February - with year-to-date losses for Adobe now approaching 30%.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Eastman Kodakup 11.6%Nektar Therapeuticsup 3.0%Rubrikup 1.5%DOWN AFTER EARNINGS -Ulta Beautydown 8.1%Adobedown 7.4%ServiceTitandown 7.2%SentinelOnedown 4.9%Lennardown 1.3%ALSO LOWER -PAR Technology Corporationdown 22.7% after convertible debt offeringInsulet Corporationdown 7.6%

Reports Q4 revenue $21.8M vs. $29.2M last year. "2025 was a pivotal year for Nektar as we saw successful and transformative Phase 2 data readouts for rezpegaldesleukin," said Howard Robin, President and CEO of Nektar. "The data highlighted the promise and differentiation of our novel Treg mechanism in two inflammatory dermatological disease settings of atopic dermatitis and alopecia areata. In early 2026, we reported the 52-week treatment data for rezpegaldesleukin. These data provide hope that complete clearance of disease could be possible for patients with monthly and quarterly maintenance dosing of rezpegaldesleukin. With our strengthened financial position following the recent financing, we look forward to initiating our Phase 3 program in atopic dermatitis in June of this year, while we continue to advance our earlier TNFR2 agonist antibody and bispecific program toward the clinic."